Loxo Oncology: Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control Platform

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company, and Foghorn Therapeutics Inc., announced a strategic collaboration to create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control® platform.